Ovid Therapeutics Inc (OVID)

$2.30 +0.09 (4.07%)
Market Cap 412.47M
Revenue (ttm) 7.25M
Net Income (ttm) -17.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -240.14%
Debt to Equity Ratio 0.00
Volume 2,061,900
Avg Vol 2,300,704
Day's Range N/A - N/A
Shares Out 186.64M
Stochastic %K 30%
Beta 0.16
Analysts Strong Sell
Price Target $5.16

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the tr...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 661 7661
Fax: 646 661 4027
Address:
Hudson Commons, 441 9th Avenue 14th Floor, New York, United States
Gollum00
Gollum00 Jun. 11 at 8:06 PM
$OVID WTF
2 · Reply
BioTechHealthX
BioTechHealthX Jun. 4 at 10:02 AM
$OVID Ovid Therapeutics (NASDAQ: OVID) is not the loudest biotech penny stock under $5, but its stronger cash runway, neurology-focused pipeline, and improved balance sheet could make it one of the more interesting small-cap healthcare stocks to watch this June. https://biotechhealthx.com/biotech-news/is-ovid-therapeutics-ovid-a-good-biotech-stock-to-buy-before-the-market-notices/
0 · Reply
focafoca99
focafoca99 Jun. 3 at 11:11 AM
$OVID elected Dr. Anna Greka to its board, expanding the board to seven directors.
0 · Reply
michaelhearn
michaelhearn Jun. 3 at 12:06 AM
$OVID broke in a hurry. Needs to get above 2.60
0 · Reply
BioTechHealthX
BioTechHealthX May. 31 at 7:22 AM
$CRBU $INAB $MIST $NRXP $OVID Looking for the best biotech penny stocks to buy or watch this June? These low-priced healthcare stocks carry major catalysts, real revenue stories, FDA momentum, and the kind of volatility that can move fast. https://biotechhealthx.com/biotech-news/top-10-best-biotech-penny-stocks-to-buy-this-june/
1 · Reply
StockConsultant
StockConsultant May. 28 at 2:11 AM
$OVID Therapeutics stock watch, good day, attempting to move higher off the 2.43 support area at https://stockconsultant.com/?OVID
0 · Reply
Dubbyy
Dubbyy May. 26 at 10:42 AM
$OVID Check out this article from TipRanks | Ovid Therapeutics: Advancing Seizure Pipeline and Neuropsychiatric Programs Support Buy Rating and Unchanged $4 Price Target | https://tipranks.onelink.me/WJho/yq9e8ot2
0 · Reply
StockConsultant
StockConsultant May. 22 at 1:25 PM
$OVID Therapeutics stock watch, pullback to 2.4 support area with good trade quality at https://stockconsultant.com/?OVID
0 · Reply
Tonydarien
Tonydarien May. 20 at 4:03 PM
$OVID been trading in range of 2.38 - 2.44. Anyone expecting a breakout in near future?
0 · Reply
Jtlo
Jtlo May. 20 at 1:47 PM
$OVID same trajectory as $SLS
0 · Reply
Latest News on OVID
Ovid Therapeutics Transcript: AGM 2026

Jun 10, 2026, 10:30 AM EDT - 2 days ago

Ovid Therapeutics Transcript: AGM 2026

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Jun 4, 2026, 7:00 AM EDT - 8 days ago

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

Jun 3, 2026, 7:00 AM EDT - 9 days ago

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

Ovid Therapeutics price target raised to $7 from $5 at Roth Capital

2026-05-14T14:49:13.000Z - 4 weeks ago

Ovid Therapeutics price target raised to $7 from $5 at Roth Capital

Ovid Therapeutics reports Q1 EPS (12c), consensus (11c)

2026-05-12T12:02:41.000Z - 4 weeks ago

Ovid Therapeutics reports Q1 EPS (12c), consensus (11c)

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

May 12, 2026, 7:00 AM EDT - 4 weeks ago

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 4 weeks ago

Ovid Therapeutics Quarterly report: Q1 2026

Ovid Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 4 weeks ago

Ovid Therapeutics Earnings release: Q1 2026

Ovid Therapeutics Slides: Corporate presentation

May 12, 2026, 7:00 AM EDT - 4 weeks ago

Ovid Therapeutics Slides: Corporate presentation

Ovid Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Ovid Therapeutics Proxy statement: Proxy filing

Ovid Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Ovid Therapeutics Proxy statement: Proxy filing

Ovid Therapeutics files to sell 29.86M shares of common stock for holders

2026-04-21T20:36:47.000Z - 7 weeks ago

Ovid Therapeutics files to sell 29.86M shares of common stock for holders

Ovid Therapeutics Registration statement: Registration filing

Apr 21, 2026, 8:00 AM EDT - 7 weeks ago

Ovid Therapeutics Registration statement: Registration filing

Ovid Therapeutics Transcript: Status update

Apr 14, 2026, 9:30 AM EDT - 2 months ago

Ovid Therapeutics Transcript: Status update

Ovid Therapeutics Slides: Status update

Apr 14, 2026, 9:30 AM EDT - 2 months ago

Ovid Therapeutics Slides: Status update

Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright

2026-04-09T10:10:35.000Z - 2 months ago

Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Ovid Therapeutics price target raised to $7 from $5 at Wedbush

2026-03-20T12:01:46.000Z - 3 months ago

Ovid Therapeutics price target raised to $7 from $5 at Wedbush

Ovid Therapeutics price target raised to $5 from $3 at Roth Capital

2026-03-19T14:25:25.000Z - 3 months ago

Ovid Therapeutics price target raised to $5 from $3 at Roth Capital

Ovid Therapeutics Earnings Call Transcript: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 3 months ago

Ovid Therapeutics Earnings Call Transcript: Q4 2025

Ovid Therapeutics Annual report: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 3 months ago

Ovid Therapeutics Annual report: Q4 2025

Ovid Therapeutics Earnings release: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 3 months ago

Ovid Therapeutics Earnings release: Q4 2025

Ovid Therapeutics Slides: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 3 months ago

Ovid Therapeutics Slides: Q4 2025

Ovid Therapeutics announces Phase 1 clearance for OV4071

2026-03-18T10:16:18.000Z - 3 months ago

Ovid Therapeutics announces Phase 1 clearance for OV4071

Ovid Therapeutics reports Q4 EPS 6c, consensus (10c)

2026-03-18T10:15:47.000Z - 3 months ago

Ovid Therapeutics reports Q4 EPS 6c, consensus (10c)

Ovid Therapeutics sees cash runway into late 2028

2026-03-18T10:15:34.000Z - 3 months ago

Ovid Therapeutics sees cash runway into late 2028

Ovid Therapeutics announces OV239 data, indication expansion

2026-03-18T10:10:52.000Z - 3 months ago

Ovid Therapeutics announces OV239 data, indication expansion

Ovid Therapeutics prices 19.15M shares at $2.01 in private placement

2026-03-18T10:06:08.000Z - 3 months ago

Ovid Therapeutics prices 19.15M shares at $2.01 in private placement

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 18, 2026, 6:05 AM EDT - 3 months ago

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Mar 18, 2026, 6:00 AM EDT - 3 months ago

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Ovid Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 3:00 PM EDT - 3 months ago

Ovid Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Ovid Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 3 months ago

Ovid Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Ovid Therapeutics initiated with an Outperform at LifeSci Capital

2025-12-22T12:50:56.000Z - 6 months ago

Ovid Therapeutics initiated with an Outperform at LifeSci Capital

Ovid Therapeutics reports Phase 1 results for KCC2, OV350 IV

2025-12-18T13:05:15.000Z - 6 months ago

Ovid Therapeutics reports Phase 1 results for KCC2, OV350 IV

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Dec 18, 2025, 8:00 AM EST - 6 months ago

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Ovid Therapeutics files to sell 125.06M shares of common stock for holders

2025-12-15T22:30:46.000Z - 6 months ago

Ovid Therapeutics files to sell 125.06M shares of common stock for holders

Ovid Therapeutics Registration statement: Registration Filing

Dec 15, 2025, 7:00 AM EST - 6 months ago

Ovid Therapeutics Registration statement: Registration Filing

Ovid Therapeutics initiated with a Buy at Roth Capital

2025-12-11T10:15:12.000Z - 6 months ago

Ovid Therapeutics initiated with a Buy at Roth Capital

Ovid Therapeutics appoints Kaufmann as Chief Medical Officer

2025-12-02T12:11:39.000Z - 6 months ago

Ovid Therapeutics appoints Kaufmann as Chief Medical Officer

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Dec 2, 2025, 7:00 AM EST - 6 months ago

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Ovid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright

2025-11-24T11:21:59.000Z - 7 months ago

Ovid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright

Leerink bullish on Ovid Therapeutics, initiates with an Outperform

2025-11-17T11:25:04.000Z - 7 months ago

Leerink bullish on Ovid Therapeutics, initiates with an Outperform

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 7 months ago

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Ovid Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 2:00 AM EST - 7 months ago

Ovid Therapeutics Earnings release: Q3 2025

Ovid Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 2:00 AM EST - 7 months ago

Ovid Therapeutics Quarterly report: Q3 2025

Ovid Therapeutics Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 7 months ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Proxy statement: Proxy Filing

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Proxy statement: Proxy Filing

Oct 27, 2025, 8:00 AM EDT - 8 months ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Transcript: Study Result

Oct 3, 2025, 8:30 AM EDT - 9 months ago

Ovid Therapeutics Transcript: Study Result

Ovid Therapeutics Press release: Study Result

Oct 3, 2025, 8:30 AM EDT - 9 months ago

Ovid Therapeutics Press release: Study Result

Ovid Therapeutics Slides: Study Result

Oct 3, 2025, 8:30 AM EDT - 9 months ago

Ovid Therapeutics Slides: Study Result

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Oct 3, 2025, 7:05 AM EDT - 9 months ago

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Oct 3, 2025, 7:00 AM EDT - 9 months ago

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Aug 13, 2025, 8:00 AM EDT - 10 months ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Ovid Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 3:00 AM EDT - 10 months ago

Ovid Therapeutics Earnings release: Q2 2025

Ovid Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 3:00 AM EDT - 10 months ago

Ovid Therapeutics Quarterly report: Q2 2025

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Jul 23, 2025, 8:30 AM EDT - 11 months ago

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Jun 25, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Ovid Therapeutics Transcript: Status Update

Jun 12, 2025, 9:30 AM EDT - 1 year ago

Ovid Therapeutics Transcript: Status Update

Ovid Therapeutics Slides: Status Update

Jun 12, 2025, 9:30 AM EDT - 1 year ago

Ovid Therapeutics Slides: Status Update

Ovid Therapeutics Slides: Corporate Presentation

Jun 12, 2025, 7:00 AM EDT - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Proxy statement: Proxy Filing

May 22, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Proxy statement: Proxy Filing

May 22, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Slides: Corporate Presentation

May 16, 2025, 7:00 AM EDT - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Ovid Therapeutics Earnings release: Q1 2025

May 13, 2025, 3:00 AM EDT - 1 year ago

Ovid Therapeutics Earnings release: Q1 2025

Ovid Therapeutics Quarterly report: Q1 2025

May 13, 2025, 3:00 AM EDT - 1 year ago

Ovid Therapeutics Quarterly report: Q1 2025

Ovid Therapeutics Proxy statement: Proxy Filing

May 2, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 7, 2025, 8:45 AM EDT - 1 year ago

Ovid Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Ovid Therapeutics Slides: Corporate Presentation

Apr 5, 2025, 7:00 AM EDT - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ovid Therapeutics Slides: Corporate Presentation

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Annual report: Q4 2024

Mar 11, 2025, 3:00 AM EDT - 1 year ago

Ovid Therapeutics Annual report: Q4 2024

Ovid Therapeutics Earnings release: Q4 2024

Mar 11, 2025, 3:00 AM EDT - 1 year ago

Ovid Therapeutics Earnings release: Q4 2024

Ovid Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 3:10 PM EST - 1 year ago

Ovid Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Ovid Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 4:00 PM EST - 1 year ago

Ovid Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ovid Therapeutics Slides: Corporate Presentation

Jan 13, 2025, 7:00 AM EST - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Slides: Corporate Presentation

Dec 27, 2024, 7:00 AM EST - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Transcript: KCC2 Download Day 2024

Nov 13, 2024, 9:30 AM EST - 1 year ago

Ovid Therapeutics Transcript: KCC2 Download Day 2024

Ovid Therapeutics Slides: FY 2024

Nov 13, 2024, 9:30 AM EST - 1 year ago

Ovid Therapeutics Slides: FY 2024

Ovid Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Ovid Therapeutics Quarterly report: Q3 2024

Ovid Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Ovid Therapeutics Earnings release: Q3 2024

Ovid Therapeutics Slides: Corporate Presentation

Nov 12, 2024, 7:00 AM EST - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Slides: Corporate Presentation

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Ovid Therapeutics Slides: Corporate Presentation

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Ovid Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 3:00 AM EDT - 1 year ago

Ovid Therapeutics Quarterly report: Q2 2024

Ovid Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 3:00 AM EDT - 1 year ago

Ovid Therapeutics Earnings release: Q2 2024

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Jul 23, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Jul 1, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Ovid Therapeutics Slides: Corporate Presentation

Jun 17, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

Jun 17, 2024, 6:55 AM EDT - 2 years ago

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

May 14, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

Ovid Therapeutics Slides: Corporate Presentation

May 14, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics Quarterly report: Q1 2024

May 14, 2024, 3:00 AM EDT - 2 years ago

Ovid Therapeutics Quarterly report: Q1 2024

Ovid Therapeutics Earnings release: Q1 2024

May 14, 2024, 3:00 AM EDT - 2 years ago

Ovid Therapeutics Earnings release: Q1 2024

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Ovid Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics Proxy statement: Proxy Filing

Ovid Therapeutics Slides: Corporate Presentation

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Mar 8, 2024, 8:00 AM EST - 2 years ago

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Ovid Therapeutics Annual report: Q4 2023

Mar 8, 2024, 2:00 AM EST - 2 years ago

Ovid Therapeutics Annual report: Q4 2023

Ovid Therapeutics Earnings release: Q4 2023

Mar 8, 2024, 2:00 AM EST - 2 years ago

Ovid Therapeutics Earnings release: Q4 2023

Ovid Therapeutics Slides: Corporate Presentation

Mar 7, 2024, 7:00 AM EST - 2 years ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 8:00 AM EST - 2 years ago

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Ovid Therapeutics Slides: Corporate Presentation

Jan 8, 2024, 7:00 AM EST - 2 years ago

Ovid Therapeutics Slides: Corporate Presentation

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Dec 1, 2023, 7:30 AM EST - 2 years ago

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Gollum00
Gollum00 Jun. 11 at 8:06 PM
$OVID WTF
2 · Reply
BioTechHealthX
BioTechHealthX Jun. 4 at 10:02 AM
$OVID Ovid Therapeutics (NASDAQ: OVID) is not the loudest biotech penny stock under $5, but its stronger cash runway, neurology-focused pipeline, and improved balance sheet could make it one of the more interesting small-cap healthcare stocks to watch this June. https://biotechhealthx.com/biotech-news/is-ovid-therapeutics-ovid-a-good-biotech-stock-to-buy-before-the-market-notices/
0 · Reply
focafoca99
focafoca99 Jun. 3 at 11:11 AM
$OVID elected Dr. Anna Greka to its board, expanding the board to seven directors.
0 · Reply
michaelhearn
michaelhearn Jun. 3 at 12:06 AM
$OVID broke in a hurry. Needs to get above 2.60
0 · Reply
BioTechHealthX
BioTechHealthX May. 31 at 7:22 AM
$CRBU $INAB $MIST $NRXP $OVID Looking for the best biotech penny stocks to buy or watch this June? These low-priced healthcare stocks carry major catalysts, real revenue stories, FDA momentum, and the kind of volatility that can move fast. https://biotechhealthx.com/biotech-news/top-10-best-biotech-penny-stocks-to-buy-this-june/
1 · Reply
StockConsultant
StockConsultant May. 28 at 2:11 AM
$OVID Therapeutics stock watch, good day, attempting to move higher off the 2.43 support area at https://stockconsultant.com/?OVID
0 · Reply
Dubbyy
Dubbyy May. 26 at 10:42 AM
$OVID Check out this article from TipRanks | Ovid Therapeutics: Advancing Seizure Pipeline and Neuropsychiatric Programs Support Buy Rating and Unchanged $4 Price Target | https://tipranks.onelink.me/WJho/yq9e8ot2
0 · Reply
StockConsultant
StockConsultant May. 22 at 1:25 PM
$OVID Therapeutics stock watch, pullback to 2.4 support area with good trade quality at https://stockconsultant.com/?OVID
0 · Reply
Tonydarien
Tonydarien May. 20 at 4:03 PM
$OVID been trading in range of 2.38 - 2.44. Anyone expecting a breakout in near future?
0 · Reply
Jtlo
Jtlo May. 20 at 1:47 PM
$OVID same trajectory as $SLS
0 · Reply
2tacos_plis
2tacos_plis May. 14 at 5:10 PM
$OVID Hedge fund amateur hour today. Buys and sells in increments of 100/200 shares. 🥱😵😴😴
0 · Reply
2tacos_plis
2tacos_plis May. 13 at 8:58 PM
$OVID Loaded up on 2 lots. 1500 shares at $2.78 and 1500 shares at $2.74. At the bottom of the trend headed to the top $3.40 and beyond. Just fuck’n do it! 🙂🤙🏼🥃
0 · Reply
Dubbyy
Dubbyy May. 13 at 7:16 AM
$OVID here is a future runner
0 · Reply
perchedcats
perchedcats May. 13 at 2:41 AM
$MGNX i’ve accumulated 30.000 shares—last time i was so big into a biotech was $OVID at $0.30. ASCO abstracts about to get released. floor substantially higher with cash on hand over $300M 🤞
2 · Reply
JesusIsKing1
JesusIsKing1 May. 12 at 5:27 PM
$OVID Added. Like the momentum in this one.
0 · Reply
dl42
dl42 May. 12 at 11:29 AM
$OVID https://investors.ovidrx.com/news/news-details/2026/Ovid-Therapeutics-Reports-Business-Updates-and-First-Quarter-2026-Financial-Results/default.aspx
0 · Reply
michaelhearn
michaelhearn May. 11 at 11:59 PM
$OVID pre market tomorrow!
1 · Reply
NorthStarStats
NorthStarStats May. 11 at 1:26 PM
Setups to watch, not trade recommendations $HUT $APLD $RKLB $SKYT $OVID
0 · Reply
PrinceTheGreat
PrinceTheGreat May. 8 at 10:52 PM
$OVID Trump Is Planning to Fire FDA Commissioner Marty Makary - WSJ https://share.google/lMkkjh5yKoPFbisnj
0 · Reply
michaelhearn
michaelhearn May. 8 at 9:36 PM
$OVID added twice this week
0 · Reply
Jdstoner30
Jdstoner30 May. 7 at 1:08 PM
$OVID lfg!
0 · Reply
zoneclassman1
zoneclassman1 May. 5 at 5:37 PM
$CABA $OVID Great calls Jack made me nice profit here.
0 · Reply